Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx raises £500,000 to progess cancer trial

ValiRx has one drug, VAL201, going through phase I/II trials
ValiRx raises £500,000 to progess cancer trial
ValiRx has one drug, VAL201, going through phase I/II trials

ValiRx (LON:VAL) has raised £503,000 gross through a placing at 12p per to fund its drug development pipeline.

ValiRx has one drug, VAL201, going through  phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401.

Satu Vainikka, chief executive said: "We are delighted to be able to raise additional funds through this equity placing in a challenging market.

“These funds will enable the company to progress the clinical trial activity that was recently announced."

PhilW.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Related Articles

shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
Drugs
February 06 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.